
FUTURE PLANS AND [REDACTED]

FUTURE PLANS

See “Business — Our Strategies” for a detailed description of our future plans and strategies.

[REDACTED]

We estimate that we will receive [REDACTED] from the [REDACTED] of approximately HK\$[REDACTED] million after deducting professional fees, [REDACTED] commissions and other fees incurred in connection with the [REDACTED] at the [REDACTED] of HK\$[REDACTED] per [REDACTED].

We intend to use the [REDACTED] we receive from the [REDACTED] as follows:

- Approximately [REDACTED]%, or HK\$[REDACTED] million, will be used to fund the continuing clinical R&D activities, as well as costs and expenses of registration filings and preliminary commercialisation efforts for our Core Product, GH21:
 - o approximately [REDACTED]%, or HK\$[REDACTED] million, will be used for advancing our phase 1b/2, phase 2 and phase 3 clinical trials and registration filings for GH21 in combination with Garsorasib, including the payment to clinical trial sites, CROs, SMOs and CDMOs, costs for raw materials and consumables to be used, expenses on registration filings procedures, and preliminary manufacturing and commercialisation expenses. We target to complete the first part of phase 1b/2 clinical trial in patients with solid tumours harbouring KRAS^{G12C} mutation in the fourth quarter of 2026, subject to treatment needs of enrolled patients, and the second part of phase 1b/2 clinical trial on naive patients with KRAS^{G12C} in the fourth quarter of 2027. We also plan to commence the phase 3 clinical trial in the fourth quarter of 2027 which is expected to complete in 2029, upon the completion of which a NDA application will be submitted to the NMPA in 2029; we also target to complete the phase 2 clinical trial in patients with KRAS^{G12C} inhibitor resistance by the fourth quarter of 2027, and submit the NDA application for conditional approval to the NMPA in 2028;
 - o approximately [REDACTED]%, or HK\$[REDACTED] million, will be used for advancing our phase 1b/2 and subsequent clinical trials for GH21 in combination with Osimertinib, including the payment to clinical trial sites, CROs, SMOs and CDMOs, and costs for raw materials and consumables to be used. We target to complete the first part of phase 1b/2 clinical trial in patients with third-generation EGFR-TKI resistant NSCLC in the fourth quarter of 2026, and commence the second part of phase 1b/2 clinical trial in the first quarter of 2027, which is expected to complete by 2029; and
 - o approximately [REDACTED]%, or HK\$[REDACTED] million, will be used for advancing our phase 1, phase 2 and subsequent clinical trials for GH21 in combination with GH55 in patients with solid tumours with MAPK pathway activation, including the payment to clinical trial sites, CROs, SMOs and CDMOs, and costs for raw materials and consumables to be used. We received the IND approval from the NMPA in January 2026 and commenced the phase 1 clinical trial in March 2026, and we target to complete it in the first quarter of 2027.

The CRO, SMO and CDMO fees for all GH21-related clinical trials mentioned above are approximately HK\$[REDACTED] million in aggregate.

- Approximately [REDACTED]%, or HK\$[REDACTED] million, will be used to fund phase 1, phase 2 and subsequent clinical trials for GH56:
 - o approximately [REDACTED]%, or HK\$[REDACTED] million, will be used to fund trials including the ongoing phase 1 clinical trial on patients with solid tumours with MTAP deletion, as well as the phase 2 clinical trial in China in patients with solid tumours for GH56, including the payment to clinical trial sites, CROs, SMOs and CDMOs, and costs for raw materials and consumables to be used. We plan to commence the phase 2 clinical trial in China in the first quarter in 2027. We also target to complete the phase 1 clinical trial in the third quarter of 2027;

FUTURE PLANS AND [REDACTED]

- o approximately [REDACTED]%, or HK\$[REDACTED] million, will be used to fund the phase 1 clinical trial in the U.S. and subsequent clinical trials for GH56, including the payment to relevant CRO. We target to commence the phase 1 clinical trial in the U.S. in the first quarter of 2027;

The CRO, SMO and CDMO fees in aggregate for all GH56-related clinical trials mentioned above are approximately HK\$[REDACTED] million.

- Approximately [REDACTED]%, or HK\$[REDACTED] million, will be used to fund phase 1 and subsequent clinical trials for GH2616 in patients with solid tumours with TP53 mutant and WGD, including the payment to clinical trial sites, CDMOs, and costs for raw materials and consumables to be used. We target to complete phase 1 clinical trial in the second quarter of 2027; and

The CDMO fees in aggregate for all GH2616-related clinical trials mentioned above are approximately HK\$[REDACTED] million.

- Approximately [REDACTED]%, or HK\$[REDACTED] million, will be used to fund the continuing clinical R&D activities for our pre-clinical stage drug candidates GH1581, GH3595 and GH58, including the expenses on relevant studies, as well as payment to CROs and CDMOs for pre-clinical studies and early-stage clinical trials. We target to submit the IND applications to the NMPA and the FDA for GH1581 for patients with solid tumours with MSI-H and for GH3595 for patients with solid tumours with MSI-H or HRD in the third quarter of 2027. We plan to submit IND applications for GH58 to the NMPA and the FDA in 2028.

The CRO, SMO and CDMO fees for clinical trials for GH1581, GH3595 and GH58 are approximately HK\$[REDACTED] million in aggregate.

- Approximately [REDACTED]%, or HK\$[REDACTED] million, will be used for working capital and other general corporate purposes.

To the extent that the [REDACTED] of the [REDACTED] are not immediately required for the above purposes or if we are unable to put into effect any part of our development plan as intended, we will only deposit the unused [REDACTED] into short-term interest-bearing accounts at licenced commercial banks and/or other authorised financial institutions (as defined under the Securities and Futures Ordinance or applicable laws and regulations in other jurisdictions). In such event, we will comply with the appropriate disclosure requirements under the Listing Rules. We will issue an appropriate announcement if there is any material change in the above-mentioned [REDACTED].